3,905 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.6% during the 3rd quarter, Holdings Channel reports. The fund owned 10,766 shares of the biopharmaceutical company’s stock after selling 3,905 shares during the period. Commonwealth Equity Services LLC’s holdings in Regeneron Pharmaceuticals were worth $8,164,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $26,000. Armstrong Advisory Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $29,000. Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $29,000. Finally, Fiduciary Financial Advisors bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.4%

REGN stock opened at $955.47 on Friday. The stock has a market capitalization of $98.84 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 1.26 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $816.17 and a 200 day moving average of $747.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same quarter in the prior year, the business posted $11.83 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% compared to the same quarter last year. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Analyst Ratings Changes

Several research firms have commented on REGN. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Piper Sandler lifted their price objective on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research note on Monday, November 2nd. The Goldman Sachs Group increased their target price on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 7,439 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,652,693.38. This trade represents a 81.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christine Poon sold 7,830 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the sale, the director owned 5,219 shares in the company, valued at approximately $5,057,680.71. This represents a 60.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 27,028 shares of company stock valued at $25,025,950. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.